The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor

Jan J. Jobsen, Lambert Naudin ten Cate, Marnix L.M. Lybeert, Elzbieta M. van der Steen-Banasik, A.M. Scholten, Jacobus Adrianus Maria van der Palen, J. van der Palen, Annerie Slot, Marika C. Stenfert Kroese, Eltjo M. Schutter, Sabine Siesling

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

The aim of this study was to look at the impact of the number of sites with tumour involvement on outcome for patients with stage IIIA endometrioid-type endometrial carcinoma. Patients and methods: 141 patients stage IIIA were included. A central histopathological review was performed. Patients staged solely on the presence of a positive peritoneal washing were excluded. Follow-up ranged from 2 to 217 months with a median of 43 months. Endpoints of the study were locoregional recurrence rates, distant metastasis-free survival (DMFS), disease-free survival (DFS) and disease-specific survival (DSS). Results: In multivariate analyses the number of involved sites showed to be the only independent significant variable for DMFS, DFS, and DSS with a Hazard Ratio of 2.1, 2.2, and 2.2, respectively. The DSS was significantly related to the number of involved sites, with a 5-year DSS of 70.4% for one site, 42.8% for two sites, and 43.9% for three sites, respectively (p = 0.001). Conclusion: The number of involved sites outside the corpus uterine for stage IIIA seems to be a strong negative prognostic factor for stage IIIA endometrial carcinoma.
Original languageEnglish
Pages (from-to)32-36
JournalGynecologic oncology
Volume117
Issue number1
DOIs
Publication statusPublished - 2010

Keywords

  • METIS-271536
  • IR-77364

Fingerprint Dive into the research topics of 'The number of metastatic sites for stage IIIA endometrial carcinoma, endometrioid cell type, is a strong negative prognostic factor'. Together they form a unique fingerprint.

Cite this